UFP Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The unaudited consolidated results compare with Q1 2023. UFP Technologies designs and manufactures engineered products, primarily for medical-device and packaging customers.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $105.0 million | $97.8 million | +7.4% |
| Gross profit / margin | $30.1 million / 28.6% | $28.7 million / 29.4% | Margin down 0.8 percentage points |
| Operating income | $15.9 million | $12.8 million | +24.0% |
| Net income | $12.7 million | $9.7 million | +30.3% |
| Diluted EPS | $1.64 | $1.27 | +29.1% |
| Operating cash flow | $10.7 million | $1.7 million | Increased $8.9 million |
| Capital expenditures | $1.7 million | $2.2 million | Decreased $0.4 million |
Gross margin decreased primarily due to a lower build of finished goods than in the prior-year quarter and medical-market sales mix. SG&A rose 7.0% to $13.9 million, mainly reflecting higher performance-based compensation, benefits, and payroll taxes; SG&A declined slightly as a share of sales, to 13.2% from 13.3%. The effective tax rate was 17.2%, versus 18.1%.
Liquidity, debt, and balance sheet
- Cash and cash equivalents were $11.4 million at March 31, up from $5.3 million at year-end 2023. Operating cash flow of $10.7 million was partly offset by $1.7 million of investing outflows and $2.7 million of financing outflows; cash increased $6.1 million overall.
- Current assets were $150.5 million and current liabilities were $52.4 million. Inventory rose to $73.9 million from $70.2 million at year-end; management attributed the increase to inventory build for anticipated demand.
- The balance sheet reports $34.0 million of debt: $4.0 million current and $30.0 million long-term. The credit agreement includes a $40 million term loan and a revolving facility of up to $90 million, maturing December 21, 2026. The stated borrowing rate was approximately 6.6%; the company reported compliance with its covenants.
- Debt disclosure inconsistency: The debt footnote and balance sheet report $34 million outstanding, while MD&A states approximately $30 million outstanding. Investors should verify the correct amount and current revolver availability.
Business trends, outlook, and material items
- Management said sales growth was organic. Medical sales increased 7.4%, led by robotic surgery and infection-prevention products; aerospace and defense sales increased 46%. Medical represented 85.7% of sales.
- One customer generated 32.2% of Q1 sales, up from 22.3% in Q1 2023, and represented 18.6% of gross receivables at quarter-end. This concentration makes results and collections sensitive to that customer.
- The company recorded a $0.2 million expense from remeasuring DAS Medical contingent consideration. The liability was approximately $13.3 million against up to $15 million of remaining potential earn-out payments. It also paid approximately $1.7 million during the quarter on acquisition-related non-compete agreements.
- Management expects existing resources, operating cash flow, and its revolving facility to fund requirements, including capital expenditures, for the next 12 months. It plans to add manufacturing capacity and may pursue acquisitions, but gave no specific revenue, earnings, or margin guidance.
- Risks highlighted include customer concentration, reduced or canceled orders, delayed customer payments, acquisition execution and financing, debt covenant compliance, supply-chain disruption, cybersecurity, and geopolitical conflict or civil unrest. The filing specifically notes potential disruption to Dominican Republic manufacturing from unrest in nearby Haiti and broader effects of the Russia-Ukraine conflict and other conflicts.
- No material litigation was reported. Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Reconcile the $30 million versus $34 million debt disclosures and confirm undrawn borrowing capacity and covenant headroom.
- Assess dependence on the largest customer, including the rise to 32.2% of quarterly sales, and monitor receivables concentration.
- Track gross-margin recovery, finished-goods inventory, and whether planned capacity investments translate into profitable demand.
- Monitor actual outcomes and payments tied to the DAS Medical earn-out and acquisition-related non-compete obligations.
- Review potential operational exposure from Dominican Republic facilities, geopolitical events, and supply-chain or cyber disruptions.